Curious Biosimilar Issues: More Workload, But Fewer US FDA Staff Needed

The US FDA’s capacity planning formula indicates a smaller biosimilar program than a year ago, but says supplement, meeting and other work continue to increase.

Workload
Meetings and manufacturing supplements are estimated to rise in FY 2022, while one less biosimilar application is expected, compared to the current fiscal year. • Source: Alamy

Biosimilar program projections from the US Food and Drug Administration suggest fewer staff are needed than a year ago, even as several workload metrics continue to increase.

The agency’s capacity planning adjustment predictably estimated that funding for more full-time equivalent paid staff is necessary for the biosimilar...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

More from Biosimilars & Generics